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Dopaminergic receptor type 2
Infantile parkinsonism
Synaptic proteinsTyrosine hydroxylase (TH) deﬁciency is an inborn error of dopamine biosynthesis and a cause of early parkinsonism.
Two clinical phenotypes have been described. Type “B”: early onset severe encephalopathy; type “A”: later onset,
less severe and better response to L-dopa. We aimed to study the expression of several key dopaminergic and
gabaergic synaptic proteins in the cerebrospinal ﬂuid (CSF) of a series of patients with TH deﬁciency and their
possible relation with the clinical phenotype and response to L-DOPA.
Dopamine transporter (DAT), D2-receptor and vesicularmonoamine transporter (VMAT2)weremeasured in the
CSF of 10 subjectswith THdeﬁciency byWestern blot analysis. In 3 patients, data of pre- and post-treatmentwith
L-DOPAwere available, and in one of them, GABA vesicular transporter was determined. Results were compared
to an age-matched control population.
The concentration of D2-receptors in CSFwas signiﬁcantly higher in patients with TH deﬁciency than in controls.
Similarly, DAT and vesicular monoamine transporter type 2 were up-regulated. Studies performed before L-
DOPA, and on L-DOPA therapy showed a paradoxical response with D2 receptor expression increase as L-Dopa
doses and homovanillic concentration gradually raised in a B phenotype patient. The opposite results were
found in two patients with A phenotype. However, this is a very small sample, and further studies are needed
to conclude robust differences between phenotypes.
Synaptic proteins are detectable in the CSF and their quantiﬁcation can be useful for understanding the pathophys-
iology of neurotransmitter defects and potentially to adjust and personalize treatments in the future.
© 2014 Elsevier Inc. All rights reserved.1. Introduction
Tyrosine hydroxylase (TH) deﬁciency (OMIM191290) is a rare auto-
somal recessive inborn error of dopamine transmission. TH converts
tyrosine into L-DOPA, the direct precursor of catecholamine biosynthe-
sis (Fig. 1). This enzymatic conversion is a rate-limiting step in the bio-
synthesis of catecholamines. Around sixty patients with TH deﬁciency
have been reportedworldwide [1–11]. TH deﬁciency causes a neurolog-
ical disease with predominant extrapyramidal signs and a variable
response to L-DOPA. Although different neurological manifestations
have been described (recessive form of Segawa disease, infantiletal Sant JoandeDeu, Passeig Sant
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a comprehensive review[7] has divided them into two main forms:
type A, a progressive hypokinetic-rigid syndrome plus dystonia, with
onset in infancy or childhood; and type B, a complex encephalopathy
with neonatal or early infancy onset (hypokinetic-rigid syndrome plus
developmental delay, a variety of movement disorders and occasionally
epilepsy). Generally, motor and cognitive prognosis is worse in type B.
However, the pathophysiological aspects thatmay underlie these differ-
ences have beenpoorly described. Although THdeﬁciency is a disease of
neuronal communication, the role of key synaptic proteins responsible
for dopaminergic transmission has not been reported so far. Synaptic
transmission depends on neurotransmitter pools stored within vesicles
that undergo regulated exocytosis. In the case of dopaminergic transmis-
sion, the vesicular monoamine transporter-2 (VMAT2) is responsible
for the loading of dopamine (DA) and other monoamines into synapticns as useful biomarkers in tyrosine hydroxylase deﬁciency, Mol. Genet.
Fig. 1. Schematic representation of dopaminergic synapse and synaptic proteins studied.
VMAT2 (vesicular monoamine transporter 2).
2 C. Ortez et al. / Molecular Genetics and Metabolism xxx (2014) xxx–xxxvesicles [12]. The DA transporter (DAT) carries DA across the
plasmalemmal membrane from the synaptic cleft into the cytoplasm
[13]. The central actions of DA are mediated by ﬁve distinct receptors
that belong to the G-protein receptor family (Fig. 1). They are classiﬁed
as D1-like (D1 and D5) and D2-like (D2, D3 and D4), and their interac-
tion with dopamine translates into activation/inhibition of speciﬁc
neurons and circuitries [14]. D2-receptor (D2 R) genetic mutations are
related to postural abnormalities, bradykinesia, impaired coordination
and prolonged periods of immobility [15]. These symptoms are also
characteristic of patients suffering from other dopaminergic neuro-
transmission disorders. Following recent reports on the co-release of
classical neurotransmitters and on interactions between different
neurotransmission pathways, we wanted to explore the role of the
GABA vesicular transporter (GABAVT), which gives an estimation of
GABA release, after L-DOPA treatment.
The detection and quantiﬁcation of dopaminergic and GABAergic
synaptic proteins in the CSF of a control population have been previous-
ly reported by our group [16]. We aimed to study synaptic proteins
involved in dopaminergic and GABAergic transmission in the CSF of
patients with TH deﬁciency, in order to relate their expression to the
different clinical phenotypes and L-DOPA response.2. Methods
2.1. Patients
Ten patients with diverse pathogenic mutations in tyrosine hydrox-
ylase genewere diagnosed atHospital Sant Joan deDéu, Barcelona, from
2002 to 2010. Some of them have been already published as individual
case reports [5,6,8,17]. Clinical, biochemical and molecular data of
the whole series are described in Table 1. Five patients were classiﬁed
as “B” phenotype and ﬁve as “A”. Follow-up and detailed response to
L-dopa treatment are also reported in Table 1.2.2. CSF studies
CSF samples from patients were collected by lumbar puncture as
previously described [18,19]. After lumbar puncture, the ﬁrst ten
drops were used for routine cytochemical/microbiological studies and
then CSF was immediately stored in 4 aliquots at −80 °C until the
moment of analysis. Biogenic amines metabolites and synaptic proteins
were analyzed in the next 20 drops.Please cite this article as: C. Ortez, et al., Cerebrospinalﬂuid synaptic protei
Metab. (2014), http://dx.doi.org/10.1016/j.ymgme.2014.10.014Biogenic amines metabolites were analyzed by high performance
liquid chromatography (HPLC) with electrochemical and ﬂuorescence
detection, respectively. Results were compared to our reference values
that were established in a control population from our geographical
area. Details of reference interval establishmentwere reported elsewhere
[19].
The synaptic proteins, VMAT2, DAT and D2R, involved in dopaminer-
gic transmission, were analyzed by Western blot. In 3 patients (5, 6, 7 in
Table 1), these proteins were studied before and after L-dopa treatment,
and included GABA vesicular transporter (GABA VT), which gives an esti-
mation of GABA release, in patient 5. Furthermore, GFAP (glial ﬁbrillar
acidic protein) was also analyzed as loading and protein concentration
inner control of the technique. A total of 40 μl of CSF sample was loaded
into the gel andproteinswere separated on 10% sodiumdodecyl sulfate-
polyacrylamide gels (SDS-PAGE) and transferred to polyvinylidene
diﬂuoride (PVDF) membranes (AmershamTM HybondTM –ECL, GE
Healthcare). Membranes were blocked in TBST buffer (0.02 M Tris-base,
pH7.6, 0.8% NaCl, 0.1% Tween 20) with 5% dried skimmed milk for
60 min. Anti-DAT extracellular loop (1:1000; Sigma®), anti-D2 R
(1:1000;Millipore®), anti-VMAT2 (1:1000; Santa Cruz Biotechnology®),
anti-GABA VT (1/500; Millipore®) and anti-GFAP (1:1000; Santa Cruz
Biotechnology®) antibodieswere added, and incubated at 4 °C overnight.
Membraneswerewashed three timeswith TBST buffer and then incubat-
ed with appropriate anti-rabbit (1:3000, Promega®) or anti-mouse
(1:5000, Promega®) IgG secondary antibodies at room temperature for
1 h. The blot was then washed six times with TBST and signal was
revealed with ECL (Pierce® ECL Western Blotting Substract, Thermo
Scientiﬁc). Relative levels of each protein were quantiﬁed by measuring
optical densities (OD) of the corresponding bands with Quantity One ®
V 4.3.1. software. CSF total protein was measured by standard automated
procedures in an Architect ci8200 analyzer (Abbott, USA). Results of
synaptic proteins were compared to a control population whose CSF
samples were submitted to our laboratory for analysis under suspicion
of nervous system infection.. Exclusion criteria were diagnosis of viral or
bacterial meningitis, a chronic neurological condition, and hematic
or xanthochromic CSF (blood contamination). We studied 3 to 5 age-
matched controls for every patient with the exception of the oldest
patients, aged 17 and 30 years. Since HSJD is a pediatric hospital, we
could only recruit two and one controls respectively.
Samples from patients were obtained in accordance with the Helsinki
Declaration of 1964, as revised in 2000. Written informed consent was
obtained from legal guardians of all patients included. The ethical
committee of the Hospital Sant Joan de Déu approved the study.2.3. Statistical analysis
All analyses were performed by using SPSS 20.0. Student's t-test was
used to ﬁnd differences in synaptic proteins between patients and con-
trols. A P value b0.05 was considered signiﬁcant.3. Results
3.1. Differences in synaptic proteins between patients (before treatment)
and controls
Total protein concentration in the CSF samples from patients
and controls was within normal limits according to different age
ranges (data not shown). DAT, D2R, VMAT2 and GABA vesicular
transporter were clearly detectable at the expected molecular
weight using conventional western blot analysis in all the CSF sam-
ples studied (Fig. 2). The concentration of dopaminergic proteins
D2R, DAT and VMAT2 in CSF measured by the average optical den-
sity (AOD) was signiﬁcantly higher in pre-treated patients than in
controls (p b 0.0001) (Fig. 3A).ns as useful biomarkers in tyrosine hydroxylase deﬁciency, Mol. Genet.
Table 1
Clinical, biochemical and molecular data of the patients included.
Patient 1 2 3 4 5 6 7 8 9 10
Origin Greek Spanish Turkish
Onset age/sex 3 m/F 3 m/F 1 m/F 3 m/F 5 m/F 3 m/F 6 m/F 4 m/F 3 y/M 2.5 y/M
Age at diagnosis/treatment 2 y/2 y 5 m/5 m 5 m/5 m 8 y/8 y 3 y/3 y 2.5 y/2.5 y 19 m/19 m 11 m/11 m 17 y/3 y 30 y/2.5 y
Oculogyric crisis ++ + ++ + ++ ++ + − − −
Dystonia Generalized Intermitent
segmental
Intermitent Generalized − Upper
limbs
Pes Equino Varo − Generalized (truncal and
cervical prominent)
Generalized
Tremor ++ + + + + + ++ ++ − +
Hypokinesia ++ ++ ++ ++ ++ ++ ++ ++ + ++
Rigidity − − − − ++ ++ + + + ++
Autonomic dysfunction + + + + + + − − − −
Response to L-dopa Gradual improvement.






















N N N N N










Difﬁcult to asses due to
dysarthria, but
relatively preserved



















Phenotype B B B B B A A A A A










































21 19 17 30 15 15 32 19 22 25







+: slight to moderate. ++: severe.−: absent. F: female. M: male. M: months. MR: mental retardation. NI: no information. N: normalization of symptoms. Y: years.
Values of D2R, DAT and VMAT correspond to optical densities. * Normal range: 15–40 mg/dl.





































4 C. Ortez et al. / Molecular Genetics and Metabolism xxx (2014) xxx–xxx3.2. Synaptic proteins in patients before treatment according to different
clinical, biochemical and genetic characteristics
3.2.1. With regard to clinical phenotypes
the overall expression of synaptic proteins was higher in phenotype
A than in B. However, this difference was mainly due to the very high
expression of D2, DAT and VMAT2 in patients 9 and 10, in whom CSF
was obtained 24 h after the withdrawal of L-DOPA. These patients had
received long-term treatment with L-DOPA (14 and 27 years, respec-
tively) and stopped only to quantify neurotransmitters for diagnostic
purposes. The remaining patients underwent their CSF study not only
much earlier in time, but without any previous L-DOPA exposure.
When considering all patients, we observed that D2 receptors had a
higher expression in the A (AOD: 153 × 104; SEM: 346 × 103 ) than in B
(AOD: 115 × 104; SEM: 399 × 103; Student's t test was not done due to
the small size of every group). However, excluding patients 9 and 10, B
phenotype had a greater D2R expression than A (in A, AOD: 103 × 104;
SEM: 106 × 103; in “B”: AOD: 115 × 104; SEM: 399.6 × 104 ). When
individual cases were analyzed, we observed (Fig. 3B) that patients
with the B phenotype presented a broad variability of D2R expression,
with the highest values in patients 2 and 5. Patient 5 had the most
severe clinical phenotype of our series (Table 1), with generalized dyski-
nesias and severe mental retardation. Patient 2 showed an initial good
response and tolerance to L-DOPA, but treatment was discontinued for
one year and she showed generalized dyskinesias when L-dopa was
reintroduced. However, the remaining B phenotype patients had also
L-dopa induced dyskinesias without a similar high level of D2R expres-
sion. Interestingly, patient 3, who showed the most favorable outcome
amongst the B phenotype patients, had the lowest D2R expression.
Global DAT expression was also higher in A phenotype than in
B (in “A”, AOD: 137 × 104, SEM: 346 × 103, whereas in “B”: AOD:
953 × 103 SEM: 399 × 103 ). The same pattern was also observed with
VMAT2 expression (in “A”, AOD: 180 × 104, SEM: 355 × 103, and in
“B”, AOD: 106 × 104, SEM: 434 × 103).3.2.2. With regard to HVA concentration and HVA/HIAA ratio
patients with the B phenotype had in general lower concentration
(from 5 to 50 nmol/l; mean: 23.9) than phenotype A patients (from 23
to 158 nmol/l; mean: 91.8). HVA concentrations in our oldest patients
(9 and 10) were lower than expected for A phenotypes, but as already
mentioned, these patients are an exception in terms of age and long-
term L-DOPA therapy. HVA/HIAA ratio followed a similar behavior,
being much lower in B phenotype patients (range 0.03–0.25; mean:
0.10), compared to Aphenotype patients (range 0.42–1.06;mean: 0.77).
Finally, we did not observe any association between genotype and
the expression of the synaptic proteins studied.Fig. 2. Immunoblot analysis of the proteins included in the study. VMAT2 (vesicular
monoamine transporter 2), D2 (D2 receptor), DAT (dopamine transporter), GABAVT
(GABA vesicular transporter), and GFAP (glial ﬁbrillar acidic protein).
Please cite this article as: C. Ortez, et al., Cerebrospinalﬂuid synaptic protei
Metab. (2014), http://dx.doi.org/10.1016/j.ymgme.2014.10.0143.3. Synaptic proteins before and after L-dopa treatment
In those patients with CSF study before L-dopa treatment and on
L-dopa treatment we observed that the expression of synaptic proteins,
and notably D2R, was different depending on the phenotypes. Patients
with the A phenotype (6 and 7) had a decrease in the expression of
D2R after treatment that corresponds to a simultaneous increase in
their HVA concentrations (Fig. 4). Patient 5 (B phenotype) had several
CSF studies performed at progressively higher L-dopa doses, that showed
an unexpected higher expression of D2R in spite of a global tendency of
increase and normalization in HVA concentrations (Fig. 4A). Moreover
GABAVT, an estimator of GABA release had also a progressive increase
in parallel to L-dopa doses and HVA concentration (Fig. 4,B and C).
4. Discussion
In this study we aimed to describe the expression of some key syn-
aptic dopaminergic and gabaergic proteins in the CSF of ten patients
with TH deﬁciency, the relationship with the clinical phenotype and
with the response to L-DOPA. Our series has a relatively signiﬁcant
size, since fewer than sixty patients have been reported worldwide
[1–11,17]. To our knowledge, this is the ﬁrst study to measure the con-
centration of synaptic proteins involved in neurotransmission in the CSF
of patients with TH deﬁciency.
One of the most intriguing features in this disease is the pathophysi-
ology of the two main different phenotypes, and in particular, the vari-
able response and tolerance to L-dopa, a factor related to the global
outcome. Patients with the severe phenotype have an early onset com-
plex encephalopathy or infantile parkinsonismwith pyramidal tract dys-
function, developmental delay, oculogyric crisis and poor or moderate
treatment response. However, some of our patients with favorable out-
come and classiﬁed as A or mild phenotype (patients 6, 7 and 8), had
also a very early start of symptoms (below 6 months of age) and a
clinical picture of complex infantile parkinsonism as severe as our B
patients. Although early introduction of treatment is related to a most
favorable outcome [7], some of our A patients with very severe early
symptoms did not start treatment until 2.5 years of age (patient 6) and
managed nonetheless to achieve a normal psychomotor development.
These considerations suggest that although phenotype classiﬁcations
are necessary and useful, in some cases it is difﬁcult to set up clear limits
and overlaps between predetermined characteristics easily appear.
In the population studied, the levels of HVA and the HVA/HIAA ratio
in CSF, as well as a positive, rapid and early response to treatment with
L-DOPA, were the main determinants of a favorable outcome, rather
than age at onset or initial clinical features.
It has been already described that the phenotypes and treatment
outcomes are related to the lowest HVA levels and a HVA/5-HIAA
ratio of less than 1 in the CSF [7,9,10]. Clinical features compatible
with dopa-responsive dystonia were the most salient features of the
two other patients with A phenotype (9 and 10). In spite of the good
outcome, both of them had rather low HVA CSF values. However, we
have not found previous data in the literature on HVA concentrations
in juvenile and adult ages (17 and 30 years) and on patients who
have received long-term treatment with L-DOPA.
In addition, it is not known what the role of the time period of dis-
continuation of L-dopa before the collection of CSF for analysis is.
With regard to the study of synaptic proteins, all were easily de-
tectable at the expected molecular weight by the same procedures
as previously reported [16]. We observed a baseline signiﬁcant
higher expression of D2R, DAT and VMAT in our patients compared
to our age-matched control population. This is compatible with an up-
regulation of post-synaptic D2 receptor and a high functioning of
dopamine reuptake (DAT) as a consequence of a chronic low dopamine
exposition at the synaptic cleft.
Althoughwe expected to ﬁnd the highest D2R expression in all those
patients with very low values of HVA, this ﬁnding was not constant.ns as useful biomarkers in tyrosine hydroxylase deﬁciency, Mol. Genet.
Fig. 3. A. Boxplot of optic densities of dopaminergic synaptic proteins for patients and controls. *p b 0.001. B. Schematic representation of optical density values in patients (green) and
controls (blue). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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Fig. 4. A: Expression of synaptic proteins before and post-L-dopa in patients with A phenotypes (6 and 7) and B phenotype (5). B: D2 receptor andGABAVT expression after L-dopa gradual
increase in patient 5 (B phenotype). Pictures of the immunoblots are shownunder the respective graph bar. C: Increase andnormalization of HVA (homovanilic acid, nmol/l) concentrations
in consonance with L-dopa gradual increase in patient 5.
6 C. Ortez et al. / Molecular Genetics and Metabolism xxx (2014) xxx–xxxMost of them, patients 2, 5, 9 and 10 predictably presented very high
D2R expression together with very low HVA values. However, patients
3 and 4, also with extremely low HVA levels, showed the lowest D2R
expression.
Interestingly, we found relevant differences in the expression of D2R
when comparing the CSF before and after L-DOPA treatment. Two pa-
tients with A phenotype (6 and 7) achieved an adequate D2R response
by decreasing its expression (downregulation) as L-DOPA doses and
HVA concentration raised. On the other hand, our only B patient
(5)with several CSF samples, at gradually higher L-DOPAdoses present-
ed a paradoxical response by progressively increasing its expression
(permanent upregulation) even in the presence of normal HVA values.
It has been widely demonstrated in basic research studies that dopa-
mine plays a vital role in brain development from the ﬁrst prenatal
stages [7,20]. Dopamine is also a neurotrophic factor involved in synap-
se formation and brain wiring during development [21]. Chronic early
dopamine deﬁciency might cause very diverse functional and micro-
structural abnormalities that result in mental retardation and various
neurological disabilities. The abnormal behavior of D2R in our patient
could be a consequence of this persistent severe dopamine deﬁciency.
Unfortunately, we do not have other post-L-DOPA CSF samples frompa-
tients with a similar outcome. Our study shows different D2R expres-
sion regarding L-DOPA response in both phenotypes, in a very small
sample of patients. These results remain preliminary and need further
collaborative studies in order to conclude robust differences between
phenotypes.
Studies about dopaminergic receptors in Parkinson's Disease (PD),
an adquired status of dopaminergic denervation, have shown structural
changes in the striatal microcircuit, including an abnormal functional
interaction between D1 and D2 receptors in the control of motor func-
tion[22]. Because PD is primarily characterized by the degeneration of
dopaminergic neurons projecting into the striatum, several studies
have been performed to characterize the modiﬁcation of the main
forms of striatal neuronal plasticity in experimental models of PD[23].Please cite this article as: C. Ortez, et al., Cerebrospinalﬂuid synaptic protei
Metab. (2014), http://dx.doi.org/10.1016/j.ymgme.2014.10.014These morphological changes are permanent and as a consequence,
the basal ganglia enters an ‘abnormal state’ that eventually precludes
the opportunity for the restoration of normal motor function through
dopamine replacement therapy at later time points[22]. In particular,
dopamine depletion, in addition to direct performance effects, will
result in inhibitory learning in the indirect pathway that will impair fu-
ture performance and learning even when dopamine signaling is re-
stored [24]. Several studies suggest that loss of dopamine signaling at
D2 receptors can invert corticostriatal plasticity in the striatopalidal
pathway, which could underlie aberrant learning. Diminished dopa-
mine will favor the indirect “inhibitory” striatopallidal NOGO pathway
because of greater activity in D2-expressing MSNs as a consequence of
less activation of D2 R [24]. Therefore, the abnormal motor patterns
observed in status of dopamine depletion like PD and TH deﬁciency
disease probably reﬂect the induction of abnormal neural circuitries
within the basal ganglia network, that can be more or less reversible
with L-DOPA treatment in each patient.
In summary, the analysis of synaptic proteins' expression provides
an original approach for the study of inborn errors of neurotransmitters.
In particular, these studies may introduce novel insights into the patho-
physiology of neuronal communication in these disorders. Our study in
TH deﬁciency contributes preliminary data that suggest abnormal D2R
behavior. However the sample is short and heteregenous and further
collaborative studies will be necessary to conﬁrm these ﬁndings. The
ﬁeld of synaptoproteomics is currently improving and will probably
increase the understanding of disease mechanisms and contribute to
personalized therapeutic strategies in the future. Further studies are
required to improve our knowledge of the mild and severe phenotypes
of TH deﬁciency.Conﬂict of interest
Authors state that there is no conﬂict of interest.ns as useful biomarkers in tyrosine hydroxylase deﬁciency, Mol. Genet.
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